nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—CA14—Furosemide—dilated cardiomyopathy	0.0999	0.152	CbGbCtD
Nilotinib—CA6—Furosemide—dilated cardiomyopathy	0.0949	0.144	CbGbCtD
Nilotinib—CA7—Furosemide—dilated cardiomyopathy	0.0827	0.126	CbGbCtD
Nilotinib—CA12—Furosemide—dilated cardiomyopathy	0.071	0.108	CbGbCtD
Nilotinib—CA9—Furosemide—dilated cardiomyopathy	0.071	0.108	CbGbCtD
Nilotinib—CA1—Furosemide—dilated cardiomyopathy	0.0664	0.101	CbGbCtD
Nilotinib—CA4—Furosemide—dilated cardiomyopathy	0.0624	0.0949	CbGbCtD
Nilotinib—CA2—Furosemide—dilated cardiomyopathy	0.0574	0.0872	CbGbCtD
Nilotinib—CYP2C8—Spironolactone—dilated cardiomyopathy	0.0213	0.0323	CbGbCtD
Nilotinib—ABCB1—Lisinopril—dilated cardiomyopathy	0.0163	0.0249	CbGbCtD
Nilotinib—ABCB1—Spironolactone—dilated cardiomyopathy	0.0144	0.0219	CbGbCtD
Nilotinib—CA3—pericardium—dilated cardiomyopathy	0.00633	0.0764	CbGeAlD
Nilotinib—EPHA2—pulmonary artery—dilated cardiomyopathy	0.00622	0.0751	CbGeAlD
Nilotinib—CYP2C9—cardial valve—dilated cardiomyopathy	0.00544	0.0658	CbGeAlD
Nilotinib—CDC42BPB—cardiac ventricle—dilated cardiomyopathy	0.00242	0.0292	CbGeAlD
Nilotinib—Drug eruption—Spironolactone—dilated cardiomyopathy	0.00226	0.0224	CcSEcCtD
Nilotinib—MAPK8—myocardium—dilated cardiomyopathy	0.00206	0.0249	CbGeAlD
Nilotinib—TIE1—myocardium—dilated cardiomyopathy	0.00179	0.0216	CbGeAlD
Nilotinib—MAPK11—heart—dilated cardiomyopathy	0.0016	0.0194	CbGeAlD
Nilotinib—Breast pain—Spironolactone—dilated cardiomyopathy	0.0016	0.0158	CcSEcCtD
Nilotinib—CDC42BPB—heart—dilated cardiomyopathy	0.00159	0.0192	CbGeAlD
Nilotinib—HCK—myocardium—dilated cardiomyopathy	0.00156	0.0189	CbGeAlD
Nilotinib—EPHA3—heart—dilated cardiomyopathy	0.00151	0.0182	CbGeAlD
Nilotinib—CA3—cardiac ventricle—dilated cardiomyopathy	0.00149	0.018	CbGeAlD
Nilotinib—MAPK8—heart—dilated cardiomyopathy	0.00144	0.0174	CbGeAlD
Nilotinib—EPHA4—myocardium—dilated cardiomyopathy	0.00142	0.0171	CbGeAlD
Nilotinib—Flank pain—Lisinopril—dilated cardiomyopathy	0.00141	0.014	CcSEcCtD
Nilotinib—CA3—myocardium—dilated cardiomyopathy	0.0014	0.0169	CbGeAlD
Nilotinib—Hyperkalaemia—Spironolactone—dilated cardiomyopathy	0.00137	0.0136	CcSEcCtD
Nilotinib—CDC42BPB—cardiac atrium—dilated cardiomyopathy	0.00136	0.0164	CbGeAlD
Nilotinib—CA14—cardiac ventricle—dilated cardiomyopathy	0.00135	0.0163	CbGeAlD
Nilotinib—EPHB4—cardiac ventricle—dilated cardiomyopathy	0.00132	0.0159	CbGeAlD
Nilotinib—Dysaesthesia—Lisinopril—dilated cardiomyopathy	0.00131	0.013	CcSEcCtD
Nilotinib—MAP4K1—heart—dilated cardiomyopathy	0.00131	0.0158	CbGeAlD
Nilotinib—TEK—cardiac ventricle—dilated cardiomyopathy	0.00126	0.0152	CbGeAlD
Nilotinib—TIE1—heart—dilated cardiomyopathy	0.00125	0.0151	CbGeAlD
Nilotinib—Gynaecomastia—Spironolactone—dilated cardiomyopathy	0.00125	0.0123	CcSEcCtD
Nilotinib—EPHB4—myocardium—dilated cardiomyopathy	0.00124	0.015	CbGeAlD
Nilotinib—Drug eruption—Furosemide—dilated cardiomyopathy	0.00123	0.0122	CcSEcCtD
Nilotinib—BRAF—heart—dilated cardiomyopathy	0.00119	0.0144	CbGeAlD
Nilotinib—Hypomagnesaemia—Furosemide—dilated cardiomyopathy	0.00119	0.0118	CcSEcCtD
Nilotinib—TEK—myocardium—dilated cardiomyopathy	0.00119	0.0143	CbGeAlD
Nilotinib—EPHB3—heart—dilated cardiomyopathy	0.00119	0.0143	CbGeAlD
Nilotinib—Blood triglycerides increased—Furosemide—dilated cardiomyopathy	0.00116	0.0115	CcSEcCtD
Nilotinib—Transient ischaemic attack—Lisinopril—dilated cardiomyopathy	0.00113	0.0112	CcSEcCtD
Nilotinib—HCK—heart—dilated cardiomyopathy	0.00109	0.0132	CbGeAlD
Nilotinib—ABL2—heart—dilated cardiomyopathy	0.00108	0.0131	CbGeAlD
Nilotinib—Thrombosis—Furosemide—dilated cardiomyopathy	0.00107	0.0106	CcSEcCtD
Nilotinib—TIE1—cardiac atrium—dilated cardiomyopathy	0.00107	0.0129	CbGeAlD
Nilotinib—Blister—Furosemide—dilated cardiomyopathy	0.00105	0.0104	CcSEcCtD
Nilotinib—Lethargy—Spironolactone—dilated cardiomyopathy	0.00103	0.0102	CcSEcCtD
Nilotinib—Cholestasis—Furosemide—dilated cardiomyopathy	0.000998	0.00988	CcSEcCtD
Nilotinib—EPHA4—heart—dilated cardiomyopathy	0.00099	0.012	CbGeAlD
Nilotinib—CA3—heart—dilated cardiomyopathy	0.000978	0.0118	CbGeAlD
Nilotinib—MAP2K5—myocardium—dilated cardiomyopathy	0.00097	0.0117	CbGeAlD
Nilotinib—MAPK14—heart—dilated cardiomyopathy	0.000913	0.011	CbGeAlD
Nilotinib—LCK—heart—dilated cardiomyopathy	0.000909	0.011	CbGeAlD
Nilotinib—FGR—heart—dilated cardiomyopathy	0.000909	0.011	CbGeAlD
Nilotinib—Psoriasis—Lisinopril—dilated cardiomyopathy	0.000905	0.00896	CcSEcCtD
Nilotinib—Gastritis—Spironolactone—dilated cardiomyopathy	0.000895	0.00886	CcSEcCtD
Nilotinib—PDGFRB—cardiac ventricle—dilated cardiomyopathy	0.000892	0.0108	CbGeAlD
Nilotinib—CA14—heart—dilated cardiomyopathy	0.000888	0.0107	CbGeAlD
Nilotinib—Disturbance in attention—Furosemide—dilated cardiomyopathy	0.000875	0.00866	CcSEcCtD
Nilotinib—EPHB4—heart—dilated cardiomyopathy	0.000865	0.0105	CbGeAlD
Nilotinib—Eosinophilia—Spironolactone—dilated cardiomyopathy	0.000865	0.00857	CcSEcCtD
Nilotinib—KIT—myocardium—dilated cardiomyopathy	0.000859	0.0104	CbGeAlD
Nilotinib—EPHA2—heart—dilated cardiomyopathy	0.000849	0.0103	CbGeAlD
Nilotinib—EPHA4—cardiac atrium—dilated cardiomyopathy	0.000847	0.0102	CbGeAlD
Nilotinib—PDGFRB—myocardium—dilated cardiomyopathy	0.000839	0.0101	CbGeAlD
Nilotinib—CA3—cardiac atrium—dilated cardiomyopathy	0.000836	0.0101	CbGeAlD
Nilotinib—TEK—heart—dilated cardiomyopathy	0.000828	0.01	CbGeAlD
Nilotinib—Hypocalcaemia—Furosemide—dilated cardiomyopathy	0.000828	0.0082	CcSEcCtD
Nilotinib—Hyperuricaemia—Furosemide—dilated cardiomyopathy	0.000817	0.00809	CcSEcCtD
Nilotinib—Gout—Furosemide—dilated cardiomyopathy	0.000812	0.00804	CcSEcCtD
Nilotinib—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.000805	0.00797	CcSEcCtD
Nilotinib—Hearing impaired—Furosemide—dilated cardiomyopathy	0.000796	0.00788	CcSEcCtD
Nilotinib—ABL1—cardiac ventricle—dilated cardiomyopathy	0.000795	0.00961	CbGeAlD
Nilotinib—EPHB6—heart—dilated cardiomyopathy	0.000792	0.00956	CbGeAlD
Nilotinib—Hyperlipidaemia—Lisinopril—dilated cardiomyopathy	0.000789	0.00781	CcSEcCtD
Nilotinib—Blood uric acid increased—Furosemide—dilated cardiomyopathy	0.000772	0.00764	CcSEcCtD
Nilotinib—Renal failure—Spironolactone—dilated cardiomyopathy	0.000766	0.00758	CcSEcCtD
Nilotinib—CA14—cardiac atrium—dilated cardiomyopathy	0.00076	0.00918	CbGeAlD
Nilotinib—PDGFRA—heart—dilated cardiomyopathy	0.00075	0.00906	CbGeAlD
Nilotinib—ABL1—myocardium—dilated cardiomyopathy	0.000748	0.00904	CbGeAlD
Nilotinib—Pleural effusion—Lisinopril—dilated cardiomyopathy	0.000742	0.00735	CcSEcCtD
Nilotinib—EPHB4—cardiac atrium—dilated cardiomyopathy	0.00074	0.00894	CbGeAlD
Nilotinib—EPHA2—cardiac atrium—dilated cardiomyopathy	0.000726	0.00877	CbGeAlD
Nilotinib—TEK—cardiac atrium—dilated cardiomyopathy	0.000708	0.00856	CbGeAlD
Nilotinib—Endocrine disorder—Lisinopril—dilated cardiomyopathy	0.000686	0.00679	CcSEcCtD
Nilotinib—EPHB6—cardiac atrium—dilated cardiomyopathy	0.000677	0.00818	CbGeAlD
Nilotinib—MAP2K5—heart—dilated cardiomyopathy	0.000677	0.00818	CbGeAlD
Nilotinib—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.000661	0.00655	CcSEcCtD
Nilotinib—CSF1R—heart—dilated cardiomyopathy	0.000661	0.00798	CbGeAlD
Nilotinib—CA4—cardiac ventricle—dilated cardiomyopathy	0.000653	0.00789	CbGeAlD
Nilotinib—Breast pain—Lisinopril—dilated cardiomyopathy	0.000652	0.00645	CcSEcCtD
Nilotinib—Chest discomfort—Lisinopril—dilated cardiomyopathy	0.000643	0.00636	CcSEcCtD
Nilotinib—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.000632	0.00626	CcSEcCtD
Nilotinib—Ventricular extrasystoles—Lisinopril—dilated cardiomyopathy	0.000629	0.00623	CcSEcCtD
Nilotinib—Photosensitivity—Furosemide—dilated cardiomyopathy	0.000626	0.0062	CcSEcCtD
Nilotinib—Oropharyngeal pain—Lisinopril—dilated cardiomyopathy	0.000625	0.00619	CcSEcCtD
Nilotinib—Alopecia—Spironolactone—dilated cardiomyopathy	0.000618	0.00612	CcSEcCtD
Nilotinib—Deafness—Furosemide—dilated cardiomyopathy	0.000615	0.00609	CcSEcCtD
Nilotinib—CA4—myocardium—dilated cardiomyopathy	0.000614	0.00742	CbGeAlD
Nilotinib—Gout—Lisinopril—dilated cardiomyopathy	0.000609	0.00603	CcSEcCtD
Nilotinib—Leukocytosis—Lisinopril—dilated cardiomyopathy	0.000605	0.00599	CcSEcCtD
Nilotinib—KIT—heart—dilated cardiomyopathy	0.0006	0.00725	CbGeAlD
Nilotinib—Creatinine increased—Lisinopril—dilated cardiomyopathy	0.000597	0.00591	CcSEcCtD
Nilotinib—PDGFRB—heart—dilated cardiomyopathy	0.000586	0.00708	CbGeAlD
Nilotinib—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.000585	0.0058	CcSEcCtD
Nilotinib—MAP2K5—cardiac atrium—dilated cardiomyopathy	0.000579	0.00699	CbGeAlD
Nilotinib—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.000576	0.0057	CcSEcCtD
Nilotinib—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.000575	0.0057	CcSEcCtD
Nilotinib—Neck pain—Lisinopril—dilated cardiomyopathy	0.000575	0.0057	CcSEcCtD
Nilotinib—CSF1R—cardiac atrium—dilated cardiomyopathy	0.000565	0.00683	CbGeAlD
Nilotinib—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.000565	0.00559	CcSEcCtD
Nilotinib—Lethargy—Furosemide—dilated cardiomyopathy	0.000561	0.00556	CcSEcCtD
Nilotinib—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.000559	0.00553	CcSEcCtD
Nilotinib—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.000552	0.00547	CcSEcCtD
Nilotinib—Wheezing—Lisinopril—dilated cardiomyopathy	0.000552	0.00547	CcSEcCtD
Nilotinib—Influenza like illness—Lisinopril—dilated cardiomyopathy	0.000552	0.00547	CcSEcCtD
Nilotinib—Malaise—Spironolactone—dilated cardiomyopathy	0.000549	0.00544	CcSEcCtD
Nilotinib—CA1—heart—dilated cardiomyopathy	0.000549	0.00663	CbGeAlD
Nilotinib—Leukopenia—Spironolactone—dilated cardiomyopathy	0.000545	0.0054	CcSEcCtD
Nilotinib—CA2—cardiac ventricle—dilated cardiomyopathy	0.000542	0.00654	CbGeAlD
Nilotinib—Fluid retention—Lisinopril—dilated cardiomyopathy	0.00054	0.00534	CcSEcCtD
Nilotinib—Blood urea increased—Lisinopril—dilated cardiomyopathy	0.000537	0.00532	CcSEcCtD
Nilotinib—Photophobia—Lisinopril—dilated cardiomyopathy	0.000534	0.00529	CcSEcCtD
Nilotinib—ABL1—heart—dilated cardiomyopathy	0.000522	0.00631	CbGeAlD
Nilotinib—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.000515	0.0051	CcSEcCtD
Nilotinib—Discomfort—Spironolactone—dilated cardiomyopathy	0.000512	0.00507	CcSEcCtD
Nilotinib—Dehydration—Furosemide—dilated cardiomyopathy	0.000512	0.00507	CcSEcCtD
Nilotinib—CA2—myocardium—dilated cardiomyopathy	0.000509	0.00615	CbGeAlD
Nilotinib—Pulmonary oedema—Lisinopril—dilated cardiomyopathy	0.000506	0.00501	CcSEcCtD
Nilotinib—PDGFRB—cardiac atrium—dilated cardiomyopathy	0.000501	0.00605	CbGeAlD
Nilotinib—Confusional state—Spironolactone—dilated cardiomyopathy	0.000501	0.00496	CcSEcCtD
Nilotinib—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.000501	0.00496	CcSEcCtD
Nilotinib—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.000487	0.00482	CcSEcCtD
Nilotinib—Muscular weakness—Furosemide—dilated cardiomyopathy	0.000485	0.0048	CcSEcCtD
Nilotinib—Abdominal distension—Furosemide—dilated cardiomyopathy	0.000479	0.00474	CcSEcCtD
Nilotinib—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.000475	0.0047	CcSEcCtD
Nilotinib—Hepatic function abnormal—Lisinopril—dilated cardiomyopathy	0.000472	0.00468	CcSEcCtD
Nilotinib—Eosinophilia—Furosemide—dilated cardiomyopathy	0.000471	0.00466	CcSEcCtD
Nilotinib—Photosensitivity—Lisinopril—dilated cardiomyopathy	0.00047	0.00465	CcSEcCtD
Nilotinib—Pancreatitis—Furosemide—dilated cardiomyopathy	0.000466	0.00462	CcSEcCtD
Nilotinib—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.000466	0.00461	CcSEcCtD
Nilotinib—Eczema—Lisinopril—dilated cardiomyopathy	0.000459	0.00455	CcSEcCtD
Nilotinib—ABL1—cardiac atrium—dilated cardiomyopathy	0.000447	0.0054	CbGeAlD
Nilotinib—Pollakiuria—Furosemide—dilated cardiomyopathy	0.000439	0.00435	CcSEcCtD
Nilotinib—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.000436	0.00431	CcSEcCtD
Nilotinib—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.000434	0.0043	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.000429	0.00425	CcSEcCtD
Nilotinib—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.000429	0.00425	CcSEcCtD
Nilotinib—CA4—heart—dilated cardiomyopathy	0.000429	0.00518	CbGeAlD
Nilotinib—Arthritis—Lisinopril—dilated cardiomyopathy	0.000425	0.0042	CcSEcCtD
Nilotinib—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.000423	0.00419	CcSEcCtD
Nilotinib—Renal failure—Furosemide—dilated cardiomyopathy	0.000417	0.00413	CcSEcCtD
Nilotinib—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.000414	0.0041	CcSEcCtD
Nilotinib—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.000413	0.00409	CcSEcCtD
Nilotinib—Diplopia—Lisinopril—dilated cardiomyopathy	0.000413	0.00409	CcSEcCtD
Nilotinib—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00041	0.00405	CcSEcCtD
Nilotinib—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.000401	0.00397	CcSEcCtD
Nilotinib—Face oedema—Lisinopril—dilated cardiomyopathy	0.000398	0.00395	CcSEcCtD
Nilotinib—Urticaria—Spironolactone—dilated cardiomyopathy	0.000395	0.00391	CcSEcCtD
Nilotinib—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000393	0.00389	CcSEcCtD
Nilotinib—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.000387	0.00383	CcSEcCtD
Nilotinib—Dehydration—Lisinopril—dilated cardiomyopathy	0.000384	0.0038	CcSEcCtD
Nilotinib—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.000376	0.00372	CcSEcCtD
Nilotinib—Urethral disorder—Furosemide—dilated cardiomyopathy	0.000373	0.00369	CcSEcCtD
Nilotinib—Breast disorder—Lisinopril—dilated cardiomyopathy	0.000373	0.00369	CcSEcCtD
Nilotinib—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.000369	0.00365	CcSEcCtD
Nilotinib—CA4—cardiac atrium—dilated cardiomyopathy	0.000367	0.00443	CbGeAlD
Nilotinib—Visual impairment—Furosemide—dilated cardiomyopathy	0.000367	0.00363	CcSEcCtD
Nilotinib—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000366	0.00363	CcSEcCtD
Nilotinib—Gastritis—Lisinopril—dilated cardiomyopathy	0.000365	0.00362	CcSEcCtD
Nilotinib—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00036	0.00356	CcSEcCtD
Nilotinib—Influenza—Lisinopril—dilated cardiomyopathy	0.000357	0.00353	CcSEcCtD
Nilotinib—Eye disorder—Furosemide—dilated cardiomyopathy	0.000356	0.00352	CcSEcCtD
Nilotinib—CA2—heart—dilated cardiomyopathy	0.000356	0.0043	CbGeAlD
Nilotinib—Tinnitus—Furosemide—dilated cardiomyopathy	0.000355	0.00351	CcSEcCtD
Nilotinib—Eosinophilia—Lisinopril—dilated cardiomyopathy	0.000353	0.0035	CcSEcCtD
Nilotinib—Pruritus—Spironolactone—dilated cardiomyopathy	0.000352	0.00348	CcSEcCtD
Nilotinib—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.00035	0.00346	CcSEcCtD
Nilotinib—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.000347	0.00344	CcSEcCtD
Nilotinib—Angiopathy—Furosemide—dilated cardiomyopathy	0.000345	0.00342	CcSEcCtD
Nilotinib—Immune system disorder—Furosemide—dilated cardiomyopathy	0.000344	0.0034	CcSEcCtD
Nilotinib—Bronchitis—Lisinopril—dilated cardiomyopathy	0.000343	0.0034	CcSEcCtD
Nilotinib—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00034	0.00337	CcSEcCtD
Nilotinib—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00034	0.00337	CcSEcCtD
Nilotinib—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.000339	0.00335	CcSEcCtD
Nilotinib—Neutropenia—Lisinopril—dilated cardiomyopathy	0.000334	0.0033	CcSEcCtD
Nilotinib—Dysuria—Lisinopril—dilated cardiomyopathy	0.000334	0.0033	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.000332	0.00328	CcSEcCtD
Nilotinib—Erythema—Furosemide—dilated cardiomyopathy	0.000331	0.00328	CcSEcCtD
Nilotinib—Malnutrition—Furosemide—dilated cardiomyopathy	0.000331	0.00328	CcSEcCtD
Nilotinib—ABCG2—heart—dilated cardiomyopathy	0.000329	0.00398	CbGeAlD
Nilotinib—Dizziness—Spironolactone—dilated cardiomyopathy	0.000329	0.00325	CcSEcCtD
Nilotinib—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.000329	0.00325	CcSEcCtD
Nilotinib—Flatulence—Furosemide—dilated cardiomyopathy	0.000326	0.00323	CcSEcCtD
Nilotinib—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.000326	0.00322	CcSEcCtD
Nilotinib—Weight increased—Lisinopril—dilated cardiomyopathy	0.000325	0.00321	CcSEcCtD
Nilotinib—Dysgeusia—Furosemide—dilated cardiomyopathy	0.000324	0.00321	CcSEcCtD
Nilotinib—Weight decreased—Lisinopril—dilated cardiomyopathy	0.000323	0.0032	CcSEcCtD
Nilotinib—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.000322	0.00319	CcSEcCtD
Nilotinib—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00032	0.00317	CcSEcCtD
Nilotinib—Muscle spasms—Furosemide—dilated cardiomyopathy	0.000318	0.00315	CcSEcCtD
Nilotinib—Vomiting—Spironolactone—dilated cardiomyopathy	0.000316	0.00313	CcSEcCtD
Nilotinib—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.000314	0.0031	CcSEcCtD
Nilotinib—Rash—Spironolactone—dilated cardiomyopathy	0.000313	0.0031	CcSEcCtD
Nilotinib—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000313	0.0031	CcSEcCtD
Nilotinib—Renal failure—Lisinopril—dilated cardiomyopathy	0.000313	0.0031	CcSEcCtD
Nilotinib—Vision blurred—Furosemide—dilated cardiomyopathy	0.000312	0.00309	CcSEcCtD
Nilotinib—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.000312	0.00309	CcSEcCtD
Nilotinib—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.000312	0.00309	CcSEcCtD
Nilotinib—Headache—Spironolactone—dilated cardiomyopathy	0.000311	0.00308	CcSEcCtD
Nilotinib—Jaundice—Lisinopril—dilated cardiomyopathy	0.00031	0.00307	CcSEcCtD
Nilotinib—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.000309	0.00306	CcSEcCtD
Nilotinib—Anaemia—Furosemide—dilated cardiomyopathy	0.000306	0.00303	CcSEcCtD
Nilotinib—CA2—cardiac atrium—dilated cardiomyopathy	0.000304	0.00367	CbGeAlD
Nilotinib—CYP2B6—heart—dilated cardiomyopathy	0.000304	0.00367	CbGeAlD
Nilotinib—Haematuria—Lisinopril—dilated cardiomyopathy	0.000303	0.003	CcSEcCtD
Nilotinib—CYP2C9—heart—dilated cardiomyopathy	0.000301	0.00363	CbGeAlD
Nilotinib—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.000301	0.00298	CcSEcCtD
Nilotinib—Epistaxis—Lisinopril—dilated cardiomyopathy	0.0003	0.00297	CcSEcCtD
Nilotinib—Vertigo—Furosemide—dilated cardiomyopathy	0.000298	0.00295	CcSEcCtD
Nilotinib—Leukopenia—Furosemide—dilated cardiomyopathy	0.000297	0.00294	CcSEcCtD
Nilotinib—Nausea—Spironolactone—dilated cardiomyopathy	0.000295	0.00292	CcSEcCtD
Nilotinib—Bradycardia—Lisinopril—dilated cardiomyopathy	0.000291	0.00288	CcSEcCtD
Nilotinib—Rhinitis—Lisinopril—dilated cardiomyopathy	0.000286	0.00283	CcSEcCtD
Nilotinib—Hepatitis—Lisinopril—dilated cardiomyopathy	0.000286	0.00283	CcSEcCtD
Nilotinib—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.000283	0.00281	CcSEcCtD
Nilotinib—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.000282	0.00279	CcSEcCtD
Nilotinib—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.000281	0.00279	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00028	0.00277	CcSEcCtD
Nilotinib—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00028	0.00277	CcSEcCtD
Nilotinib—Dry mouth—Furosemide—dilated cardiomyopathy	0.000276	0.00273	CcSEcCtD
Nilotinib—Confusional state—Furosemide—dilated cardiomyopathy	0.000273	0.0027	CcSEcCtD
Nilotinib—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00027	0.00267	CcSEcCtD
Nilotinib—Tinnitus—Lisinopril—dilated cardiomyopathy	0.000266	0.00264	CcSEcCtD
Nilotinib—Shock—Furosemide—dilated cardiomyopathy	0.000266	0.00263	CcSEcCtD
Nilotinib—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000265	0.00263	CcSEcCtD
Nilotinib—Flushing—Lisinopril—dilated cardiomyopathy	0.000265	0.00262	CcSEcCtD
Nilotinib—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000265	0.00262	CcSEcCtD
Nilotinib—Skin disorder—Furosemide—dilated cardiomyopathy	0.000263	0.0026	CcSEcCtD
Nilotinib—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000261	0.00259	CcSEcCtD
Nilotinib—Angiopathy—Lisinopril—dilated cardiomyopathy	0.000259	0.00257	CcSEcCtD
Nilotinib—Anorexia—Furosemide—dilated cardiomyopathy	0.000258	0.00255	CcSEcCtD
Nilotinib—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000257	0.00255	CcSEcCtD
Nilotinib—Chills—Lisinopril—dilated cardiomyopathy	0.000256	0.00254	CcSEcCtD
Nilotinib—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.000255	0.00253	CcSEcCtD
Nilotinib—Hypotension—Furosemide—dilated cardiomyopathy	0.000253	0.0025	CcSEcCtD
Nilotinib—Alopecia—Lisinopril—dilated cardiomyopathy	0.000252	0.0025	CcSEcCtD
Nilotinib—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00025	0.00248	CcSEcCtD
Nilotinib—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000249	0.00246	CcSEcCtD
Nilotinib—Erythema—Lisinopril—dilated cardiomyopathy	0.000249	0.00246	CcSEcCtD
Nilotinib—Flatulence—Lisinopril—dilated cardiomyopathy	0.000245	0.00243	CcSEcCtD
Nilotinib—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.000243	0.00241	CcSEcCtD
Nilotinib—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000243	0.0024	CcSEcCtD
Nilotinib—Back pain—Lisinopril—dilated cardiomyopathy	0.00024	0.00238	CcSEcCtD
Nilotinib—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000239	0.00237	CcSEcCtD
Nilotinib—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000235	0.00233	CcSEcCtD
Nilotinib—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000234	0.00232	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000233	0.00231	CcSEcCtD
Nilotinib—Fatigue—Furosemide—dilated cardiomyopathy	0.000233	0.00231	CcSEcCtD
Nilotinib—Tremor—Lisinopril—dilated cardiomyopathy	0.000233	0.00231	CcSEcCtD
Nilotinib—Constipation—Furosemide—dilated cardiomyopathy	0.000231	0.00229	CcSEcCtD
Nilotinib—Pain—Furosemide—dilated cardiomyopathy	0.000231	0.00229	CcSEcCtD
Nilotinib—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.000231	0.00228	CcSEcCtD
Nilotinib—Anaemia—Lisinopril—dilated cardiomyopathy	0.00023	0.00227	CcSEcCtD
Nilotinib—Malaise—Lisinopril—dilated cardiomyopathy	0.000224	0.00222	CcSEcCtD
Nilotinib—Vertigo—Lisinopril—dilated cardiomyopathy	0.000223	0.00221	CcSEcCtD
Nilotinib—Syncope—Lisinopril—dilated cardiomyopathy	0.000223	0.00221	CcSEcCtD
Nilotinib—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.000223	0.00221	CcSEcCtD
Nilotinib—Leukopenia—Lisinopril—dilated cardiomyopathy	0.000222	0.0022	CcSEcCtD
Nilotinib—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000221	0.00219	CcSEcCtD
Nilotinib—Palpitations—Lisinopril—dilated cardiomyopathy	0.00022	0.00217	CcSEcCtD
Nilotinib—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.000218	0.00216	CcSEcCtD
Nilotinib—Cough—Lisinopril—dilated cardiomyopathy	0.000217	0.00215	CcSEcCtD
Nilotinib—Urticaria—Furosemide—dilated cardiomyopathy	0.000215	0.00213	CcSEcCtD
Nilotinib—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000214	0.00212	CcSEcCtD
Nilotinib—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000214	0.00212	CcSEcCtD
Nilotinib—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000212	0.0021	CcSEcCtD
Nilotinib—Chest pain—Lisinopril—dilated cardiomyopathy	0.000212	0.0021	CcSEcCtD
Nilotinib—Myalgia—Lisinopril—dilated cardiomyopathy	0.000212	0.0021	CcSEcCtD
Nilotinib—Anxiety—Lisinopril—dilated cardiomyopathy	0.000211	0.00209	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00021	0.00208	CcSEcCtD
Nilotinib—Discomfort—Lisinopril—dilated cardiomyopathy	0.000209	0.00207	CcSEcCtD
Nilotinib—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000207	0.00205	CcSEcCtD
Nilotinib—Confusional state—Lisinopril—dilated cardiomyopathy	0.000205	0.00203	CcSEcCtD
Nilotinib—Oedema—Lisinopril—dilated cardiomyopathy	0.000203	0.00201	CcSEcCtD
Nilotinib—Infection—Lisinopril—dilated cardiomyopathy	0.000202	0.002	CcSEcCtD
Nilotinib—Shock—Lisinopril—dilated cardiomyopathy	0.0002	0.00198	CcSEcCtD
Nilotinib—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000199	0.00197	CcSEcCtD
Nilotinib—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000199	0.00197	CcSEcCtD
Nilotinib—Tachycardia—Lisinopril—dilated cardiomyopathy	0.000198	0.00196	CcSEcCtD
Nilotinib—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000197	0.00195	CcSEcCtD
Nilotinib—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000196	0.00194	CcSEcCtD
Nilotinib—Asthenia—Furosemide—dilated cardiomyopathy	0.000194	0.00192	CcSEcCtD
Nilotinib—Anorexia—Lisinopril—dilated cardiomyopathy	0.000193	0.00191	CcSEcCtD
Nilotinib—Pruritus—Furosemide—dilated cardiomyopathy	0.000191	0.00189	CcSEcCtD
Nilotinib—Hypotension—Lisinopril—dilated cardiomyopathy	0.00019	0.00188	CcSEcCtD
Nilotinib—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000185	0.00183	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000185	0.00183	CcSEcCtD
Nilotinib—Insomnia—Lisinopril—dilated cardiomyopathy	0.000183	0.00182	CcSEcCtD
Nilotinib—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000182	0.0018	CcSEcCtD
Nilotinib—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000181	0.00179	CcSEcCtD
Nilotinib—Dizziness—Furosemide—dilated cardiomyopathy	0.000179	0.00177	CcSEcCtD
Nilotinib—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000179	0.00177	CcSEcCtD
Nilotinib—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000176	0.00175	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000175	0.00173	CcSEcCtD
Nilotinib—Fatigue—Lisinopril—dilated cardiomyopathy	0.000175	0.00173	CcSEcCtD
Nilotinib—Pain—Lisinopril—dilated cardiomyopathy	0.000173	0.00172	CcSEcCtD
Nilotinib—Constipation—Lisinopril—dilated cardiomyopathy	0.000173	0.00172	CcSEcCtD
Nilotinib—Vomiting—Furosemide—dilated cardiomyopathy	0.000172	0.0017	CcSEcCtD
Nilotinib—Rash—Furosemide—dilated cardiomyopathy	0.00017	0.00169	CcSEcCtD
Nilotinib—Dermatitis—Furosemide—dilated cardiomyopathy	0.00017	0.00169	CcSEcCtD
Nilotinib—Headache—Furosemide—dilated cardiomyopathy	0.000169	0.00168	CcSEcCtD
Nilotinib—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000167	0.00166	CcSEcCtD
Nilotinib—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000166	0.00164	CcSEcCtD
Nilotinib—ABCB1—heart—dilated cardiomyopathy	0.000162	0.00196	CbGeAlD
Nilotinib—Urticaria—Lisinopril—dilated cardiomyopathy	0.000161	0.0016	CcSEcCtD
Nilotinib—Nausea—Furosemide—dilated cardiomyopathy	0.000161	0.00159	CcSEcCtD
Nilotinib—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00016	0.00159	CcSEcCtD
Nilotinib—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00016	0.00159	CcSEcCtD
Nilotinib—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000149	0.00148	CcSEcCtD
Nilotinib—Asthenia—Lisinopril—dilated cardiomyopathy	0.000146	0.00144	CcSEcCtD
Nilotinib—Pruritus—Lisinopril—dilated cardiomyopathy	0.000144	0.00142	CcSEcCtD
Nilotinib—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000139	0.00137	CcSEcCtD
Nilotinib—Dizziness—Lisinopril—dilated cardiomyopathy	0.000134	0.00133	CcSEcCtD
Nilotinib—Vomiting—Lisinopril—dilated cardiomyopathy	0.000129	0.00128	CcSEcCtD
Nilotinib—Rash—Lisinopril—dilated cardiomyopathy	0.000128	0.00127	CcSEcCtD
Nilotinib—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000128	0.00127	CcSEcCtD
Nilotinib—Headache—Lisinopril—dilated cardiomyopathy	0.000127	0.00126	CcSEcCtD
Nilotinib—Nausea—Lisinopril—dilated cardiomyopathy	0.00012	0.00119	CcSEcCtD
Nilotinib—KIT—Signaling Pathways—CXCL2—dilated cardiomyopathy	1.17e-05	7.37e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.17e-05	7.36e-05	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—RAF1—dilated cardiomyopathy	1.17e-05	7.35e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.16e-05	7.29e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—RAC1—dilated cardiomyopathy	1.16e-05	7.28e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	1.14e-05	7.18e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—RAC1—dilated cardiomyopathy	1.14e-05	7.16e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—GPX1—dilated cardiomyopathy	1.13e-05	7.13e-05	CbGpPWpGaD
Nilotinib—CA1—Metabolism—AGT—dilated cardiomyopathy	1.13e-05	7.12e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.13e-05	7.11e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PSEN2—dilated cardiomyopathy	1.12e-05	7.08e-05	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—RAF1—dilated cardiomyopathy	1.12e-05	7.06e-05	CbGpPWpGaD
Nilotinib—MAPK8—Innate Immune System—EGFR—dilated cardiomyopathy	1.11e-05	7.01e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling by NGF—EGFR—dilated cardiomyopathy	1.11e-05	6.99e-05	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—EGFR—dilated cardiomyopathy	1.11e-05	6.99e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CXCL2—dilated cardiomyopathy	1.11e-05	6.98e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AGTR2—dilated cardiomyopathy	1.11e-05	6.98e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—RAF1—dilated cardiomyopathy	1.1e-05	6.96e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—CD36—dilated cardiomyopathy	1.1e-05	6.95e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—RAF1—dilated cardiomyopathy	1.1e-05	6.95e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PSEN2—dilated cardiomyopathy	1.1e-05	6.93e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—RAF1—dilated cardiomyopathy	1.1e-05	6.92e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.09e-05	6.85e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—CD36—dilated cardiomyopathy	1.09e-05	6.85e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—ITGB1—dilated cardiomyopathy	1.09e-05	6.85e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—RAF1—dilated cardiomyopathy	1.08e-05	6.82e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—RAF1—dilated cardiomyopathy	1.08e-05	6.78e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	1.07e-05	6.76e-05	CbGpPWpGaD
Nilotinib—BLK—Adaptive Immune System—EGFR—dilated cardiomyopathy	1.07e-05	6.74e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—ITGB1—dilated cardiomyopathy	1.06e-05	6.7e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	1.06e-05	6.7e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—RAF1—dilated cardiomyopathy	1.06e-05	6.68e-05	CbGpPWpGaD
Nilotinib—LYN—Axon guidance—EGFR—dilated cardiomyopathy	1.06e-05	6.68e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—ITGB1—dilated cardiomyopathy	1.06e-05	6.67e-05	CbGpPWpGaD
Nilotinib—ABL1—Axon guidance—EGFR—dilated cardiomyopathy	1.05e-05	6.65e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.05e-05	6.64e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—RAF1—dilated cardiomyopathy	1.04e-05	6.59e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—RAF1—dilated cardiomyopathy	1.04e-05	6.58e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PSEN2—dilated cardiomyopathy	1.04e-05	6.57e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—RAC1—dilated cardiomyopathy	1.04e-05	6.55e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.03e-05	6.49e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CD36—dilated cardiomyopathy	1.03e-05	6.48e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—RAF1—dilated cardiomyopathy	1.02e-05	6.46e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—RAC1—dilated cardiomyopathy	1.02e-05	6.46e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.02e-05	6.43e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	1.01e-05	6.38e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—ITGB1—dilated cardiomyopathy	1.01e-05	6.36e-05	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—EGFR—dilated cardiomyopathy	1e-05	6.33e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AGTR1—dilated cardiomyopathy	9.97e-06	6.28e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CXCL2—dilated cardiomyopathy	9.97e-06	6.28e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AGTR2—dilated cardiomyopathy	9.97e-06	6.28e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—ADRB1—dilated cardiomyopathy	9.96e-06	6.28e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—RAF1—dilated cardiomyopathy	9.94e-06	6.27e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—AGT—dilated cardiomyopathy	9.92e-06	6.26e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AGTR1—dilated cardiomyopathy	9.88e-06	6.23e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CXCL2—dilated cardiomyopathy	9.76e-06	6.15e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AGTR2—dilated cardiomyopathy	9.76e-06	6.15e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—RAF1—dilated cardiomyopathy	9.73e-06	6.14e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.7e-06	6.11e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—RAC1—dilated cardiomyopathy	9.69e-06	6.11e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—RAF1—dilated cardiomyopathy	9.69e-06	6.11e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—RAF1—dilated cardiomyopathy	9.63e-06	6.07e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling by NGF—EGFR—dilated cardiomyopathy	9.59e-06	6.05e-05	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—TNF—dilated cardiomyopathy	9.56e-06	6.03e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—RAF1—dilated cardiomyopathy	9.55e-06	6.02e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—ADRB2—dilated cardiomyopathy	9.46e-06	5.96e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—RAC1—dilated cardiomyopathy	9.45e-06	5.96e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—RAF1—dilated cardiomyopathy	9.45e-06	5.96e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—RAF1—dilated cardiomyopathy	9.45e-06	5.96e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—RAF1—dilated cardiomyopathy	9.42e-06	5.94e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—ADRB2—dilated cardiomyopathy	9.37e-06	5.91e-05	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—RAF1—dilated cardiomyopathy	9.35e-06	5.89e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CXCR3—dilated cardiomyopathy	9.27e-06	5.84e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD36—dilated cardiomyopathy	9.27e-06	5.84e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AGTR2—dilated cardiomyopathy	9.25e-06	5.83e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CXCL2—dilated cardiomyopathy	9.25e-06	5.83e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—RAF1—dilated cardiomyopathy	9.23e-06	5.82e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—RAC1—dilated cardiomyopathy	9.21e-06	5.81e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CXCR3—dilated cardiomyopathy	9.07e-06	5.72e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD36—dilated cardiomyopathy	9.07e-06	5.72e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD36—dilated cardiomyopathy	9.03e-06	5.69e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PSEN2—dilated cardiomyopathy	9.01e-06	5.68e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AGTR1—dilated cardiomyopathy	8.99e-06	5.67e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—ADRB1—dilated cardiomyopathy	8.98e-06	5.66e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—RAC1—dilated cardiomyopathy	8.95e-06	5.64e-05	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—EGFR—dilated cardiomyopathy	8.87e-06	5.59e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—RAF1—dilated cardiomyopathy	8.86e-06	5.59e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AGT—dilated cardiomyopathy	8.8e-06	5.55e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—ADRB1—dilated cardiomyopathy	8.79e-06	5.54e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—RAC1—dilated cardiomyopathy	8.76e-06	5.52e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—RAC1—dilated cardiomyopathy	8.73e-06	5.5e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—ITGB1—dilated cardiomyopathy	8.72e-06	5.5e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CXCR3—dilated cardiomyopathy	8.6e-06	5.42e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD36—dilated cardiomyopathy	8.6e-06	5.42e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—RAC1—dilated cardiomyopathy	8.55e-06	5.39e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—ADRB2—dilated cardiomyopathy	8.53e-06	5.38e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—RAC1—dilated cardiomyopathy	8.51e-06	5.36e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AGTR1—dilated cardiomyopathy	8.51e-06	5.36e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AGT—dilated cardiomyopathy	8.37e-06	5.28e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ADRB1—dilated cardiomyopathy	8.33e-06	5.25e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	8.25e-06	5.2e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	8.13e-06	5.12e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—RAC1—dilated cardiomyopathy	8.1e-06	5.11e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—ADRB2—dilated cardiomyopathy	8.07e-06	5.09e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—RAC1—dilated cardiomyopathy	8.06e-06	5.08e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	8.05e-06	5.08e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AGTR2—dilated cardiomyopathy	8e-06	5.04e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CXCL2—dilated cardiomyopathy	8e-06	5.04e-05	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—EGFR—dilated cardiomyopathy	7.99e-06	5.04e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—RAF1—dilated cardiomyopathy	7.98e-06	5.03e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	7.97e-06	5.02e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	7.76e-06	4.89e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	7.76e-06	4.89e-05	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—EGFR—dilated cardiomyopathy	7.68e-06	4.84e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AGTR1—dilated cardiomyopathy	7.67e-06	4.83e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—RAF1—dilated cardiomyopathy	7.66e-06	4.83e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—EGFR—dilated cardiomyopathy	7.57e-06	4.77e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—EGFR—dilated cardiomyopathy	7.56e-06	4.76e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—RAF1—dilated cardiomyopathy	7.53e-06	4.75e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—EGFR—dilated cardiomyopathy	7.52e-06	4.74e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AGTR1—dilated cardiomyopathy	7.51e-06	4.73e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CXCR3—dilated cardiomyopathy	7.44e-06	4.69e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD36—dilated cardiomyopathy	7.44e-06	4.69e-05	CbGpPWpGaD
Nilotinib—ABCG2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	7.43e-06	4.68e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—RAC1—dilated cardiomyopathy	7.34e-06	4.63e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	7.33e-06	4.62e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—RAC1—dilated cardiomyopathy	7.27e-06	4.59e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—ADRB2—dilated cardiomyopathy	7.27e-06	4.58e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—EGFR—dilated cardiomyopathy	7.27e-06	4.58e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.2e-06	4.54e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—TNF—dilated cardiomyopathy	7.2e-06	4.54e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—EGFR—dilated cardiomyopathy	7.16e-06	4.52e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—TNF—dilated cardiomyopathy	7.16e-06	4.52e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—EGFR—dilated cardiomyopathy	7.15e-06	4.51e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—ADRB2—dilated cardiomyopathy	7.12e-06	4.49e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AGTR1—dilated cardiomyopathy	7.11e-06	4.49e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AGT—dilated cardiomyopathy	7.01e-06	4.42e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	7.01e-06	4.42e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—RAC1—dilated cardiomyopathy	7.01e-06	4.42e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	6.99e-06	4.41e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AGT—dilated cardiomyopathy	6.95e-06	4.38e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	6.94e-06	4.37e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	6.94e-06	4.37e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—RAF1—dilated cardiomyopathy	6.89e-06	4.34e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—TNF—dilated cardiomyopathy	6.82e-06	4.3e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—EGFR—dilated cardiomyopathy	6.82e-06	4.3e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—RAF1—dilated cardiomyopathy	6.79e-06	4.28e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ADRB2—dilated cardiomyopathy	6.75e-06	4.26e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—GPX1—dilated cardiomyopathy	6.74e-06	4.25e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—EGFR—dilated cardiomyopathy	6.67e-06	4.21e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—EGFR—dilated cardiomyopathy	6.64e-06	4.19e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—RAC1—dilated cardiomyopathy	6.62e-06	4.17e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	6.61e-06	4.17e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—EGFR—dilated cardiomyopathy	6.6e-06	4.16e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—CD36—dilated cardiomyopathy	6.56e-06	4.14e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—EGFR—dilated cardiomyopathy	6.55e-06	4.13e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	6.49e-06	4.09e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—EGFR—dilated cardiomyopathy	6.48e-06	4.09e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—EGFR—dilated cardiomyopathy	6.48e-06	4.09e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—RAC1—dilated cardiomyopathy	6.47e-06	4.08e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—EGFR—dilated cardiomyopathy	6.46e-06	4.07e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—RAF1—dilated cardiomyopathy	6.43e-06	4.05e-05	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—EGFR—dilated cardiomyopathy	6.41e-06	4.04e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—EGFR—dilated cardiomyopathy	6.33e-06	3.99e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AGT—dilated cardiomyopathy	6.33e-06	3.99e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	6.32e-06	3.98e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—RAF1—dilated cardiomyopathy	6.27e-06	3.95e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—RAC1—dilated cardiomyopathy	6.27e-06	3.95e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	6.25e-06	3.94e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.15e-06	3.88e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	6.12e-06	3.86e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—RAF1—dilated cardiomyopathy	6.11e-06	3.85e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AGT—dilated cardiomyopathy	5.99e-06	3.77e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—RAF1—dilated cardiomyopathy	5.93e-06	3.74e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AGT—dilated cardiomyopathy	5.91e-06	3.73e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.84e-06	3.68e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—RAF1—dilated cardiomyopathy	5.81e-06	3.66e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.8e-06	3.66e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—RAF1—dilated cardiomyopathy	5.79e-06	3.65e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—GPX1—dilated cardiomyopathy	5.72e-06	3.61e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	5.69e-06	3.59e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—RAF1—dilated cardiomyopathy	5.67e-06	3.57e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—RAC1—dilated cardiomyopathy	5.65e-06	3.56e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—RAF1—dilated cardiomyopathy	5.64e-06	3.56e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—CD36—dilated cardiomyopathy	5.57e-06	3.51e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—RAC1—dilated cardiomyopathy	5.53e-06	3.48e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—EGFR—dilated cardiomyopathy	5.47e-06	3.45e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AGT—dilated cardiomyopathy	5.39e-06	3.4e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—RAF1—dilated cardiomyopathy	5.37e-06	3.39e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—RAF1—dilated cardiomyopathy	5.35e-06	3.37e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AGT—dilated cardiomyopathy	5.28e-06	3.33e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—EGFR—dilated cardiomyopathy	5.25e-06	3.31e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—RAC1—dilated cardiomyopathy	5.24e-06	3.3e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—EGFR—dilated cardiomyopathy	5.16e-06	3.26e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AGT—dilated cardiomyopathy	5.02e-06	3.16e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.01e-06	3.16e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AGT—dilated cardiomyopathy	5.01e-06	3.16e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—RAF1—dilated cardiomyopathy	4.87e-06	3.07e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—RAF1—dilated cardiomyopathy	4.82e-06	3.04e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—EGFR—dilated cardiomyopathy	4.72e-06	2.98e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—EGFR—dilated cardiomyopathy	4.66e-06	2.94e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—RAF1—dilated cardiomyopathy	4.65e-06	2.93e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—RAC1—dilated cardiomyopathy	4.53e-06	2.86e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—EGFR—dilated cardiomyopathy	4.41e-06	2.78e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—RAF1—dilated cardiomyopathy	4.39e-06	2.77e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AGT—dilated cardiomyopathy	4.33e-06	2.73e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—EGFR—dilated cardiomyopathy	4.3e-06	2.71e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—RAF1—dilated cardiomyopathy	4.29e-06	2.7e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GPX1—dilated cardiomyopathy	4.19e-06	2.64e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—EGFR—dilated cardiomyopathy	4.19e-06	2.64e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—RAF1—dilated cardiomyopathy	4.16e-06	2.62e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CD36—dilated cardiomyopathy	4.08e-06	2.57e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—EGFR—dilated cardiomyopathy	4.07e-06	2.57e-05	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	4.02e-06	2.53e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—EGFR—dilated cardiomyopathy	3.98e-06	2.51e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—EGFR—dilated cardiomyopathy	3.97e-06	2.5e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—EGFR—dilated cardiomyopathy	3.89e-06	2.45e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—EGFR—dilated cardiomyopathy	3.87e-06	2.44e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—RAF1—dilated cardiomyopathy	3.74e-06	2.36e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—EGFR—dilated cardiomyopathy	3.69e-06	2.32e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AGT—dilated cardiomyopathy	3.68e-06	2.32e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—EGFR—dilated cardiomyopathy	3.67e-06	2.31e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—RAF1—dilated cardiomyopathy	3.67e-06	2.31e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GPX1—dilated cardiomyopathy	3.55e-06	2.24e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—RAF1—dilated cardiomyopathy	3.47e-06	2.19e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CD36—dilated cardiomyopathy	3.46e-06	2.18e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EGFR—dilated cardiomyopathy	3.34e-06	2.1e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EGFR—dilated cardiomyopathy	3.31e-06	2.08e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—EGFR—dilated cardiomyopathy	3.19e-06	2.01e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AGT—dilated cardiomyopathy	3.11e-06	1.96e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	3.09e-06	1.95e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CD36—dilated cardiomyopathy	3.01e-06	1.9e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EGFR—dilated cardiomyopathy	3.01e-06	1.9e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—RAF1—dilated cardiomyopathy	3e-06	1.89e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—EGFR—dilated cardiomyopathy	2.94e-06	1.85e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	2.91e-06	1.84e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	2.89e-06	1.82e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EGFR—dilated cardiomyopathy	2.85e-06	1.8e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	2.84e-06	1.79e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	2.81e-06	1.77e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AGT—dilated cardiomyopathy	2.71e-06	1.71e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EGFR—dilated cardiomyopathy	2.57e-06	1.62e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	2.56e-06	1.61e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	2.53e-06	1.6e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EGFR—dilated cardiomyopathy	2.51e-06	1.58e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EGFR—dilated cardiomyopathy	2.38e-06	1.5e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EGFR—dilated cardiomyopathy	2.06e-06	1.3e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	1.91e-06	1.2e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	1.86e-06	1.17e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	1.67e-06	1.05e-05	CbGpPWpGaD
